

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Cech et al.

Application No.: To be assigned

Filed: Herewith

For: Novel Telomerase

Examiner: To Be Assigned

Art Unit: To Be Assigned

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. In accordance with 37 CFR §1.98(d), copies of references Q-S can be found in co-pending parent Application No. 09/843,676, filed April 26, 2001 (Attorney Docket no. 015389-002943US). Copies of the other references can be found in parent Application No. 08/854,050, filed May 9, 1997, now U.S. Patent No. 6,261,836 (Attorney Docket No.: 015389-002940US). If the examiner would like additional copies of these references, applicants will happily provide them.

It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the reference be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

11002 U.S. PRO
10/054611
01/18/02



Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No.

Respectfully submitted,



Hugh Wang
Reg. No. 47,163

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 650-326-2422
PA 3194153 v1